Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. AGNPF


Primary Symbol: C.AGN

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by nodaytraderon Mar 21, 2024 10:09am
208 Views
Post# 35944780

Tuesday’s Trading

Tuesday’s TradingOut of the country so catching up .
Tursday's trading brought the price by one cent and the usual kids in the sandbox were involved.
Howevee, there was one interesting new player- Credential Qtrade, which is a creature of the credit union movement-50% owned by Desjardins with the balance owned by other credit unions, including Vancity, Servis (Edmonton), Coast Capital (Surrey) and Assiniboine (Winnipeg).

As previously noted, suppressing a share price makes it difficult for Algernon to raise funds for research that can bring great relief to people suffering from a variety of painful diseases.

i wonder if the boards of these credit unions are aware of the affects of their "wealth management" activities.
<< Previous
Bullboard Posts
Next >>